- Home
- IPHA vs ZOM Comparison
IPHA vs ZOM Comparison
Compare IPHA & ZOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- ZOM
- Stock Information
- Founded
- IPHA 1999
- ZOM 2015
- Country
- IPHA France
- ZOM United States
- Employees
- IPHA N/A
- ZOM N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- ZOM Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- ZOM Health Care
- Exchange
- IPHA Nasdaq
- ZOM Nasdaq
- Market Cap
- IPHA 160.1M
- ZOM 128.4M
- IPO Year
- IPHA 2019
- ZOM N/A
- Fundamental
- Price
- IPHA $2.24
- ZOM $0.12
- Analyst Decision
- IPHA Strong Buy
- ZOM
- Analyst Count
- IPHA 1
- ZOM 0
- Target Price
- IPHA $11.50
- ZOM N/A
- AVG Volume (30 Days)
- IPHA 650.0K
- ZOM 3.4M
- Earning Date
- IPHA 03-20-2025
- ZOM 03-31-2025
- Dividend Yield
- IPHA N/A
- ZOM N/A
- EPS Growth
- IPHA N/A
- ZOM N/A
- EPS
- IPHA N/A
- ZOM N/A
- Revenue
- IPHA $36,202,722.00
- ZOM $26,727,000.00
- Revenue This Year
- IPHA N/A
- ZOM $10.28
- Revenue Next Year
- IPHA $93.37
- ZOM $28.00
- P/E Ratio
- IPHA N/A
- ZOM N/A
- Revenue Growth
- IPHA N/A
- ZOM 11.33
- 52 Week Low
- IPHA $1.29
- ZOM $0.12
- 52 Week High
- IPHA $3.51
- ZOM $0.20
- Technical
- Relative Strength Index (RSI)
- IPHA 63.01
- ZOM 41.88
- Support Level
- IPHA $2.07
- ZOM $0.12
- Resistance Level
- IPHA $2.38
- ZOM $0.12
- Average True Range (ATR)
- IPHA 0.13
- ZOM 0.00
- MACD
- IPHA 0.04
- ZOM 0.00
- Stochastic Oscillator
- IPHA 78.79
- ZOM 3.03
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About ZOM Zomedica Corp.
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.